Bicycle Therapeutics (BCYC) EBITDA Margin (2018 - 2026)
Bicycle Therapeutics (BCYC) reported EBITDA Margin of 7057.38% for Q1 2026, down 643261.0% on a YoY basis from N/an in Q1 2025, and down 16664.26% quarter-over-quarter from 42.1% in Q4 2025.
Bicycle Therapeutics (BCYC) EBITDA Margin (2018 - 2026) Analysis & Trends
Bicycle Therapeutics has reported EBITDA Margin for 9 years, with the latest figure at 7057.38% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 643261.0% year-over-year to 7057.38%; the trailing twelve-month figure through Mar 2026 stood at 350.97% (up 44176.0% YoY), and the FY2025 full-year result was 306.65%, up 16850.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 7057.38%, down from 42.1% in the prior quarter.
- The five-year high for EBITDA Margin was 42.1% in Q4 2025, with the low at 7057.38% in Q1 2026.
- Historically, EBITDA Margin has averaged 1191.58% across 5 years, with a median of 690.26% in 2022.
- Annual changes were most pronounced in 2025 — EBITDA Margin soared 147206 bps — and 2026, when it tumbled 643261 bps.
- Bicycle Therapeutics' EBITDA Margin stood at 358.56% in 2022, then tumbled by 179 bps to 999.59% in 2023, then sank by 31 bps to 1309.33% in 2024, then soared by 97 bps to 42.1% in 2025, then plunged by 16664 bps to 7057.38% in 2026.
- The last three EBITDA Margin figures came in at 7057.38% (Q1 2026), 42.1% (Q4 2025), and 504.58% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Bicycle Therapeutics | 278.04 Mn | 278.04 Mn | - | -7,057.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7,057.38% |
| Dec 31, 2025 | -42.10% |
| Sep 30, 2025 | -504.58% |
| Jun 30, 2025 | -2,768.97% |
| Mar 31, 2025 | -624.78% |
| Dec 31, 2024 | -1,309.33% |
| Sep 30, 2024 | -1,976.64% |
| Jun 30, 2024 | -428.65% |
| Mar 31, 2024 | -250.36% |
| Dec 31, 2023 | -999.59% |
| Sep 30, 2023 | -862.03% |
| Jun 30, 2023 | -382.13% |
| Mar 31, 2023 | -804.33% |
| Dec 31, 2022 | -358.56% |
| Sep 30, 2022 | -902.80% |
| Jun 30, 2022 | -294.45% |
| Mar 31, 2022 | -690.26% |
| Dec 31, 2021 | -1,139.50% |
| Sep 30, 2021 | -331.53% |
| Jun 30, 2021 | -1,017.82% |